MML Investors Services’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.1M | Buy |
215,859
+31,228
| +17% | +$1.82M | 0.04% | 458 |
|
|
2025
Q4 | $9.96M | Sell |
184,631
-74,012
| -29% | -$3.56M | 0.02% | 591 |
|
|
2025
Q3 | $11.7M | Buy |
258,643
+6,282
| +2% | +$293K | 0.03% | 499 |
|
|
2025
Q2 | $11.7M | Sell |
252,361
-104,744
| -29% | -$5.14M | 0.03% | 470 |
|
|
2025
Q1 | $21.8M | Sell |
357,105
-4,923
| -1% | -$287K | 0.07% | 272 |
|
|
2024
Q4 | $20.5M | Buy |
362,028
+48,340
| +15% | +$2.7M | 0.07% | 277 |
|
|
2024
Q3 | $16.2M | Buy |
313,688
+4,554
| +1% | +$214K | 0.06% | 309 |
|
|
2024
Q2 | $12.8M | Sell |
309,134
-81,414
| -21% | -$3.64M | 0.05% | 333 |
|
|
2024
Q1 | $21.2M | Buy |
390,548
+90,386
| +30% | +$4.6M | 0.09% | 236 |
|
|
2023
Q4 | $15.4M | Sell |
300,162
-70,752
| -19% | -$3.71M | 0.07% | 276 |
|
|
2023
Q3 | $21.5M | Sell |
370,914
-64,494
| -15% | -$3.95M | 0.12% | 187 |
|
|
2023
Q2 | $27.8M | Buy |
435,408
+16,717
| +4% | +$1.12M | 0.15% | 145 |
|
|
2023
Q1 | $29M | Buy |
418,691
+9,901
| +2% | +$698K | 0.21% | 104 |
|
|
2022
Q4 | $29.4M | Buy |
408,790
+21,331
| +6% | +$1.61M | 0.19% | 121 |
|
|
2022
Q3 | $27.5M | Sell |
387,459
-21,427
| -5% | -$1.55M | 0.21% | 98 |
|
|
2022
Q2 | $31.5M | Sell |
408,886
-4,001
| -1% | -$305K | 0.24% | 88 |
|
|
2022
Q1 | $30.2M | Buy |
412,887
+102,867
| +33% | +$6.91M | 0.21% | 99 |
|
|
2021
Q4 | $19.3M | Sell |
310,020
-111,148
| -26% | -$6.52M | 0.14% | 163 |
|
|
2021
Q3 | $24.9M | Buy |
421,168
+57,325
| +16% | +$3.78M | 0.2% | 110 |
|
|
2021
Q2 | $24.3M | Buy |
363,843
+17,651
| +5% | +$1.15M | 0.2% | 109 |
|
|
2021
Q1 | $21.9M | Buy |
346,192
+45,380
| +15% | +$2.82M | 0.21% | 113 |
|
|
2020
Q4 | $18.7M | Buy |
300,812
+33,179
| +12% | +$2.04M | 0.2% | 118 |
|
|
2020
Q3 | $16.1M | Buy |
267,633
+77,537
| +41% | +$4.67M | 0.2% | 118 |
|
|
2020
Q2 | $11.2M | Buy |
190,096
+42,931
| +29% | +$2.57M | 0.15% | 161 |
|
|
2020
Q1 | $8.2M | Buy |
147,165
+23,037
| +19% | +$1.41M | 0.14% | 173 |
|
|
2019
Q4 | $7.97M | Buy |
124,128
+27,608
| +29% | +$1.58M | 0.11% | 204 |
|
|
2019
Q3 | $4.89M | Sell |
96,520
-55,296
| -36% | -$2.6M | 0.08% | 242 |
|
|
2019
Q2 | $6.88M | Buy |
151,816
+10,346
| +7% | +$482K | 0.1% | 220 |
|
|
2019
Q1 | $6.75M | Sell |
141,470
-195
| -0.1% | -$9.71K | 0.1% | 207 |
|
|
2018
Q4 | $7.36M | Buy |
141,665
+56,128
| +66% | +$3.02M | 0.13% | 185 |
|
|
2018
Q3 | $5.31M | Buy |
85,537
+19,898
| +30% | +$1.18M | 0.09% | 232 |
|
|
2018
Q2 | $3.63M | Sell |
65,639
-2,327
| -3% | -$126K | 0.08% | 240 |
|
|
2018
Q1 | $4.3M | Sell |
67,966
-14,035
| -17% | -$903K | 0.09% | 211 |
|
|
2017
Q4 | $5.03M | Sell |
82,001
-24,368
| -23% | -$1.52M | 0.1% | 184 |
|
|
2017
Q3 | $6.78M | Sell |
106,369
-2,509
| -2% | -$146K | 0.14% | 151 |
|
|
2017
Q2 | $6.07M | Buy |
+108,878
| New | +$5.92M | 0.12% | 158 |
|
Other funds holding BMY
VCM
VPM
MML Investors Services's BMY Position: Q1 2026 in Review
MML Investors Services increased its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, buying an estimated $1.82M and bringing the position to 215,859 shares worth $13.1M. The position accounts for 0.04% of the portfolio, ranked #458.
MML Investors Services first reported a position in BMY in Q2 2017 and has held it in 36 quarters since. The position peaked at $31.5M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- MML Investors Services held 215,859 shares of Bristol-Myers Squibb worth $13.1M as of Q1 2026.
- MML Investors Services bought 31,228 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.82M.
- Bristol-Myers Squibb made up 0.04% of MML Investors Services's portfolio in Q1 2026, its #458 holding.
- MML Investors Services first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 36 quarters since.
- MML Investors Services's Bristol-Myers Squibb position peaked at $31.5M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.